Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Aceclidine+tropicamide combination · 1 trial · 1 indication
Proportion of subjects with at least a 3 line (15 letter) improvement in near visual acuity in the study eye at 1 hour post-treatment in the mITT population
| Arm | Type | Description |
|---|---|---|
| Aceclidine+tropicamide combination | EXPERIMENTAL | Aceclidine+tropicamide combination single dose (PRX-100 Ophthalmic Solution) |
| Aceclidine | ACTIVE_COMPARATOR | Aceclidine single dose |
| Vehicle | SHAM_COMPARATOR | Vehicle single dose |
| Name | Type | Description |
|---|---|---|
| Aceclidine+tropicamide combination | DRUG | Ophthalmic Solution |
| Aceclidine | DRUG | Ophthalmic Solution |
| Vehicle | DRUG | Ophthalmic Solution |
Inclusion Criteria: 1. Be able and willing to provide written informed consent and sign Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed; 2. Be able and willing to follow all instructions and attend study visits; 3. Be 48-64 years of ag...
Aceclidine + Brimonidine is an investigational small molecule combination being developed by LENZ Therapeutics for the treatment of presbyopia and other eye diseases. It is administered as an ophthalmic solution. The drug is currently in clinical development and has not been approved by the FDA.
Aceclidine + Brimonidine combines aceclidine, a miotic agent that acts on the eye's muscarinic receptors to constrict the pupil, with brimonidine, an alpha-2 adrenergic receptor agonist. This combination is designed to improve near vision in presbyopia by creating a pinhole effect through pupil constriction.
Aceclidine + Brimonidine is developed by LENZ Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol LENZ. The company is focused on developing ophthalmic therapies for presbyopia and other eye conditions.
Aceclidine + Brimonidine is in Phase 1 clinical development. It has completed one Phase 1 trial and one Phase 2 trial, both of which are finished. The drug remains investigational and is not yet approved for commercial use.
Aceclidine + Brimonidine has been studied in two completed clinical trials. NCT05936489 was a Phase 1 study evaluating plasma pharmacokinetics and safety in healthy adults with presbyopia. NCT03201562 was a Phase 2 trial of PRX-100, an earlier formulation, for early to moderate presbyopia.
Aceclidine + Brimonidine is the combination of aceclidine and brimonidine, and it is also known as LNZ101. The Phase 1 trial NCT05936489 evaluated both LNZ101 and LNZ100 ophthalmic solutions in healthy subjects with presbyopia.